Logo Logo

Rosenthal, L. Lily; Spickermann, Tabea Katharina; Ulrich, Sarah Marie; Dalla Pozza, Robert; Netz, Heinrich; Haas, Nikolaus A.; Schramm, René; Schmoeckel, Michael; Hagl, Christian; Hörer, Jürgen; Michel, Sebastian; Grinninger, Carola (2024): Single center experience with ABO-incompatible and ABO-compatible pediatric heart transplantation. Frontiers in Transplantation, 3. ISSN 2813-2440

[thumbnail of frtra-1-1452617.pdf] Published Article
frtra-1-1452617.pdf

The publication is available under the license Creative Commons Attribution.

Download (314kB)

Abstract

Introduction: The aim of this study was to analyze the results after pediatric heart transplantation (pHTx) at our single center differentiating between ABO-incompatible (ABOi) and -compatible (ABOc) procedures.

Methods and patients: We retrospectively analyzed outcomes of ABO-incompatible HTx procedures performed at our center and compared the data to ABO-compatible HTx of the same era. Eighteen children (<17 months) underwent pediatric HTx and seven of them underwent ABO-incompatible HTx between 2003 and 2015.

Results: Mechanical circulatory support as bridge to transplant was necessary in 3/7 patients before ABO-incompatible HTx and in 3/11 patients before ABO-compatible HTx. Mean waiting time on the list was 36 ± 30 days for ABO-incompatible HTx and 86 ± 65 days for ABO-compatible HTx. The 5-years re-transplant free survival was 86% following ABO-incompatible and 91% after ABO-compatible. In the cohort undergoing ABO-incompatible HTx, 2 patients showed an acute cellular rejection, while early graft failure was not observed. In the cohort undergoing ABOcompatible HTx, acute cellular rejection was observed in 9/11 patients, with early graft failure occurring in nine and CVP in two. A total of ten children were listed for ABO-incompatible HTx after 2015; however, all ten underwent an ABO-compatible transplantation.

Discussion: This study adds much needed information to the literature on ABOi-HTx by showing with a retrospective single center analysis that it is safe and leads to shorter waiting times. We conclude that strategies for ABOi-HTx should be elaborated further, potentially allowing more timely transplantation and thereby preventing waiting list complications such as the need for mechanical circulatory support and even death.

View Item
View Item